Celea Therapeutics
celeatx.com
Actively hiring
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$180M
1 round on record
Latest round
$180M
Venture round · Jul 2026 · 3 mo ago
Team
51-200
employees, estimated range
Hiring now
2
open roles
Backers
1
RA Capital Management
The money's age
Fresh money
3 months since the last round · hiring slowed
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 1
Raised a round Venture round $180M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2026 | $180M | — | morningstar.com |
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management Similar startupsby what they do, their industry and backers
Claris Bio is dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist.
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science…
Overview
Innovating Beyond. We are dedicated to advancing transformative medicines for people living with serious respiratory diseases, leveraging bold science shaped by patients' lived experiences.
News
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
BOSTON, August 25, 2026--Celea Therapeutics Will Present Phase 3 Trial Design for IPF & Key Insights from a Deupirfenidone Drug-Drug Interaction Study at ERS
Read more
Report
Celea Therapeutics begins patient dosing in global phase 3 SURPASS-IPF trial of deupirfenidone to treat idiopathic pulmonary fibrosis
Celea Therapeutics begins patient dosing in global phase 3 SURPASS-IPF trial of deupirfenidone to treat idiopathic pulmonary fibrosis
Read more
Report
Celea Therapeutics Raises $180 Million To Advance Deupirfenidone As Potential New Standard Of Care For IPF
Celea Therapeutics announced the completion of a $180 million financing round to support the development of deupirfenidone, also known as LYT-100, as a potential new standard of care for idiopathic pulmonary fibrosis (IPF).
Read more
Report
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
BOSTON, July 02, 2026--Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat IPF
Read more
Report
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis ...
Read more
Report
Tech stack
Technologies named in job postings at Celea Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$238k
Typical range
$100k – $375k
Open positions
2
2
Jobs
Senior
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $100k | $100k |
| Architect | 1 | $375k | $375k |
Highest paying role
Vice President, Regulatory Affairs
$375k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
ATS activity
Every ~14 hours
10/01/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Administrative
50% ▼
Public Policy
50% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Boston
Boston
United States
Regional office
Leadership team
2 open roles 2 posted in 90 days 50-200 est. staff $238k Avg Salary
hires for Administrative, Public Policy
6 Tide Street, Suite 400, Boston, MA 02210
Financials
Total raised
$180M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $180M | Details |